Experts applaud Amylyx for keeping its promise to withdraw ALS drug Relyvrio after trial failure
2024-04-04
临床3期临床失败
When Amylyx brought its ALS drug before the FDA in 2022, the biotech faced questions about what it would do if a crucial Phase 3 trial failed.
On Thursday, the
company announced
that it would pull the drug from the market less than a month after it
failed to show
that it slowed the disease better than a placebo. It’s a blow to Amylyx, which will let go about 70% of its workforce, but the move is earning praise for following through on its promise from 2022 that it would do “what’s right for patients,” as co-CEO Justin Klee pledged at the time.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。